对抗莱什曼病治疗的潜在阿斯科巴特过氧化酶抑制剂的研究
Ali A Rabaan1,2,3, Mohammed Abdulrahman Alshahrani4, Basim Othman5
1Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, 31,311, Dhahran, Saudi Arabia. arabaan@gmail.com.
Folia microbiologica
|August 17, 2024
概括
研究人员确定了可能抑制Leishmania donovani APX酶的天然化合物,为Leishmaniasis提供了潜在的新疗法. 这些化合物显示出有希望的类似药物的特性和口服生物可用性,用于对抗这种广泛传播的疾病.
科学领域:
- 寄生虫学的寄生虫学
- 药用化学 医学化学
- 计算生物学 计算生物学
背景情况:
- 莱什曼病是影响98个国家的重大全球健康问题,内脏性莱什曼病构成严重威胁.
- 目前对莱什曼病的治疗有局限性,包括严重的副作用和缺乏有效的疫苗,需要新的治疗策略.
研究的目的:
- 为了确定具有潜在抑制作用的天然化合物对阿斯科巴特过氧化酶 (APX) 酶在Leishmania donovani.
- 评估已识别的化合物作为潜在的抗莱什曼病剂的类似药物特性和结合亲和力.
主要方法:
- 使用定量结构-活性关系 (QSAR) 模型来选潜在的APX抑制剂.
- 进行分子对接模拟,以评估被击中化合物与目标酶的结合能量和亲和力.
- 分析了ADME毒理学特征,以预测口服生物可用性和药物相似性.
主要成果:
- 确定了9种受影响的化合物,其中雌二醇基酸具有最强的结合亲和力 (-26.31 ± 3.01 kcal / mol).
- 克洛克萨西林,辛尼丁和氨酸二酸盐也显示出显著的结合亲缘关系.
- 鉴定的化合物显示出有利的ADME毒理学概况,表明潜在的口服生物可用性.
结论:
- 雌激素酸,克洛克萨西林,辛尼丁和氨酸二酸对莱什马尼亚多诺瓦尼APX酶表现出抑制作用.
- 这些化合物代表了开发新型抗莱什曼病治疗的有希望的线索.
- 需要进一步的研究来探索这些已识别的化合物的治疗潜力.
更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
8.2K
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...